tirzepatide dose for inflammation Microdosing is an emerging approach supporting metabolic and hormonal health. By using smaller, carefully titrated doses, some patients may experience improved insulin sensitivity, reduced inflammation, and better metabolic regulation. For Frontiers | Tirzepatide against obesity

If you experience any signs of a severe allergic reaction, such as a swollen tongue, eyes or face, difficulty breathing, or shortness of breath, please seek medical treatment immediately

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

SURMOUNT OSA demonstrated after 52 weeks of treatment, participants who received tirzepatide had greater likelihood of remission or improvement to mild OSA as well as reduced apnea-hypopnea index (AHI) values, hypoxic burden, and systolic blood pressure

However, even 30 minutes of cardio a week is enough to avoid gaining weight or to support modest weight loss